(Q35226507)
Statements
1 reference
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors (English)
1 reference
Michael Menefee
Elizabeth R Plimack
Jonathan Rosenberg
Theresa LaVallee
Li Shi
Xiang-Qing Yu
Patricia Burke
Jiaqi Huang
Jaye Viner
Jennifer McDevitt
14 July 2014
1 reference
1 reference
1 reference
1 reference